BCC 2023 | Personalizing approaches in early-stage TNBC

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses insights on the latest developments and future prospects of immunotherapy for early-stage triple-negative breast cancer, touching on personalized approaches based on an improved understanding of disease biology. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.